Hanall Biopharma KRX:009420KOSPI
한올바이오파마 · Korean news coverage and regulatory filings, organized.
In Q3 2026, Hanall Biopharma reported revenue of ₩39.9bn, down 2.2% year on year, and operating profit of ₩1.3bn. Hanall Biopharma (한올바이오파마) appeared in 27 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Nov 10 with 21 articles. The most common catalyst was clinical & approvals (2). It was most often mentioned alongside Jeil Pharmaceutical and MedPacto.
Hanall Biopharma at a glance from DART filings
- Results trend
- Operating profit in 3 of the last 4 quarters; Q3 2026 operating profit of ₩1.3bn fell from the previous quarter.
- Ownership changes
- 1 5%-holder and insider ownership reports in the past 120 days (0 increases, 1 decreases).
Figures the company filed on DART, grouped by ATS View. Not a buy or sell call; see the cards below and the DART originals.
Hanall Biopharma today: up or down?
No sign-up, one tap a day. These numbers show what visitors think and are not investment advice.
Upcoming dates as filed
- Nov 16 Quarterly report filing deadlinetoday · period ending Sep 2026
Dates Hanall Biopharma stated in its DART filings. A conversion period opening does not mean new shares appear that day; bondholders must request conversion.
Hanall Biopharma quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q3 2026 | ₩39.9bn | -2.2% | ₩1.3bn margin 3.2% | ₩3.1bn |
| Q2 2026 | ₩44.3bn | +8.8% | ₩5.6bn margin 12.6% | −₩19.2bn |
| Q1 2026 | ₩40.0bn | +10.7% | ₩839m margin 2.1% | ₩275m |
| Q4 2025 derived | ₩37.5bn | +3.1% | −₩2.0bn margin −5.4% | −₩6.2bn |
| Q3 2025 | ₩40.8bn | +10.8% | ₩349m margin 0.9% | ₩299m |
| Q2 2025 | ₩40.7bn | +28.8% | ₩1.1bn margin 2.8% | ₩599m |
| Q1 2025 | ₩36.2bn | +6.0% | −₩394m margin −1.1% | −₩208m |
| Q4 2024 derived | ₩36.4bn | +14.8% | ₩2.7bn margin 7.5% | ₩1.6bn |
Hanall Biopharma ranks #1056 of 2,345 Korean listed companies by Q3 2026 operating profit. Q3 2026 Korean earnings rankings →
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Hanall Biopharma top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
Latest Hanall Biopharma news Korean headlines
-
MajorHanoll Biopharma's Imeroprobbat meets primary evaluation endpoint in refractory rheumatoid arthritis Phase 1 trial
2 more on this story · 2 outlets
-
FeaturedHanall Biopharm jumps 21% on successful rheumatoid arthritis clinical trial
1 more on this story · 1 outlets
-
Han-all Biopharma surges 20% in pre-market trading on Phase 2b success news
1 more on this story · 1 outlets
- Hanall BioPharma surges on news of clinical success from US partner컨슈머타임스 · Nov 10 09:46
-
Hanall Biopharma says Aimiroprubart proves efficacy in intractable rheumatoid arthritis
2 more on this story · 2 outlets
-
MajorHanall Biopharma 3Q operating profit 1.3 billion won, up 265.1% year-over-year
1 more on this story · 1 outlets